ReviewNature reviews. Disease primers2024
Autoimmune haemolytic anaemias.
Review in Nature reviews. Disease primers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Beyond hemolysis: redefining pediatric AIHA.Blood advances · 2026Article
- Single low-dose daratumumab enhances rituximab efficacy for sustained remission in treatment-refractory autoimmune cytopenias.Annals of hematology · 2026Article
- FcεRIγ reinforces double-negative T cell-mediated antibody-dependent cellular cytotoxicity against tumor cells.Journal of molecular cell biology · 2026Article
- CD163Biomarker research · 2026Article
- Autoimmune Hemolytic Anemia Occurring One Year Before Acute Leukemic Manifestation of Lymphoma with a Chronic Lymphocytic Leukemia Immunophenotype.Internal medicine (Tokyo, Japan) · 2026Article
- Splenic erythrophagocytosis is regulated by ALX/FPR2 signaling.Haematologica · 2026Article
- A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome.British journal of haematology · 2026Article
- Article
- B cell-driven refractory hemocytopenia in immune checkpoint inhibitor therapy: a report of two cases.Translational lung cancer research · 2026Article
- [Treatment practice and outcomes in 125 patients with autoimmune hemolytic anemia: a single-center retrospective analysis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- CSL305: A Dual Functional Therapeutic Antibody Targeting Complement C2 and FcRn.International journal of molecular sciences · 2026Article
- Clinical features, treatment and outcomes of pembrolizumab induced autoimmune hemolytic anemia.Investigational new drugs · 2026Article
- Ubiquitination and degradation of CD47 enhances macrophage phagocytosis of hemolytic erythrocytes.iScience · 2026Article
- Effect of obexelimab on the production of anti-RBC antibodies and cytokines in patients with warm autoimmune hemolytic anemia.Blood advances · 2026Article
- Lyme disease as a rare trigger for autoimmune hemolytic anemia.BMC infectious diseases · 2026Article
- Case Report: rapid exacerbation of autoimmune hemolysis and severe immune - mediated thrombocytopenia induced by piperacillin - tazobactam.Frontiers in medicine · 2026Article
- Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning.Frontiers in immunology · 2026Review
- Complement-mediated ADCP as a distinct and finite cytotoxic mechanism of monoclonal antibodies.Frontiers in immunology · 2026Article
- Small B-cell lymphoma highly suspicious for splenic marginal zone lymphoma withFrontiers in immunology · 2026Review
- Management of autoimmune hemolytic anemia.Hematology. American Society of Hematology. Education Program · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult autoimmune haemolytic anaemias (AIHAs) include different subtypes of a rare autoimmune disease in which autoantibodies targeting autoantigens expressed on the membrane of autologous red blood cells (RBCs) are produced, leading to their accelerated destruction. In the presence of haemolytic anaemia, the direct antiglobulin test is the cornerstone of AIHA diagnosis. AIHAs are classified according to the isotype and the thermal optimum of the autoantibody into warm (wAIHAs), cold and mixed AIHAs. wAIHAs, the most frequent type of AIHAs, are associated with underlying conditions in ~50% of cases. In wAIHA, IgG autoantibody reacts with autologous RBCs at 37 °C, leading to antibody-dependent cell-mediated cytotoxicity and increased phagocytosis of RBCs in the spleen. Cold AIHAs include cold agglutinin disease (CAD) and cold agglutinin syndrome (CAS) when there is an underlying condition. CAD and cold agglutinin syndrome are IgM cold antibody-driven AIHAs characterized by classical complement pathway-mediated haemolysis. The management of wAIHAs has long been based around corticosteroids and splenectomy and on symptomatic measures and non-specific cytotoxic agents for CAD. Rituximab and the development of complement inhibitors, such as the anti-C1s antibody sutimlimab, have changed the therapeutic landscape of AIHAs, and new promising targeted therapies are under investigation.
Indexed as
Identifiers
39487134What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.